Lanadelumab for the prevention of hereditary angioedema attacks: A real‐world UK audit
Allergy2022Vol. 78(5), pp. 1369–1371
Citations Over TimeTop 16% of 2022 papers
Anthony D. Dorr, Charu Chopra, Tanya Coulter, John Dempster, Magdalena Dziadzio, Tariq El‐Shanawany, Tomaz Garcez, Mark Gompels, Richard Herriot, Rashmi Jain, Marcel Levi, Lorena Lorenzo, Inas Makki, Elizabeth Mapazire, Sai Murng, Sadia Noorani, Sinisa Savic, Cathal Steele, Christine Symons, Michael Tarzi, Patrick Yong, Sorena Kiani‐Alikhan
Abstract
Appendix S1: Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Related Papers
- → Hereditary Angioedema with Normal C1 Inhibitor: Clinical Symptoms and Course(2007)134 cited
- → Preliminary results of a non-interventional single-center study evaluating the efficacy of long-term use of lanadelumab in routine clinical practice in the Russian Federation(2023)2 cited
- → Complement Component Analysis in Angioedema(1975)11 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)